As a result of a 6-month selection process, Abnova (Taiwan) Corporation has signed the Guan-Rong Collaboration Agreement with Dongguan Biotech Industrial Development Co., Ltd (Dongguan Biotech, Dongguan, China) and Hukui Biotechnology Corporation (Hukui Biotech, Taipei, Taiwan) on May 21st 2015. Abnova Diagnostics (Dongguan) Limited, which is wholly owned by Abnova (Taiwan) Corporation, has entered the Dongguan Songshan Lake Science and Technology Industrial Park as Abnova’s headquarters in China to facilitate cross-strait biotechnology industry cooperation.
Guan-Rong Plan was proposed by John Hsuan, the founder of Hukui Biotech, to establish a platform for cross-strait collaboration of biotechnology industry and business development. Entrusted by Dongguan Municipal Government, Hukui Biotech selected qualified biotech companies with great potential and high standard products as candidates. With the support of SASAC*-investigated Dongguan Biotech, the selected companies, on an agency basis, can acquire sales permission for mainland China. Aiming to create a win-win situation for the collaboration, market expansion will begin from Guan-Rong city to Guang-Dong Province and targeting the whole country as its goal. With the experience in regulations, clinical trials and product certifications provided by Dongguan City and Hukui Biotech, biotech companies from Taiwan will be able to accelerate the process of custom clearance and enter the Chinese biotech trading market in advance.
With extensive experience in antibody production, Abnova cooperated with TANAKA Holding Co., Ltd (Tokyo, Japan) and developed a rapid test kit for diabetes. Abnova’s Diabetes Personal A1c Rapid Test Kit will make its first debut for the Chinese IVD market, as part of the Guan-Rong project. As of 2013, there are about 114 million adults who suffered from diabetes in China, accounting for one-third of diabetic patients worldwide. On average, for every 100 adults, 11.6 individuals have diabetes but more than half of them are unware of the disease and have not been diagnosed by doctors. Fasting blood sugar test (FBS test) is the common method to monitor blood sugar level. However, the sensitivity and specificity of FBS test is affected by fluctuation of blood glucose level, and the test result cannot reflect long-term blood sugar control. On the other hand, World Health Organization (WHO) has recognized the level of HbA1c can be used as a diagnostic standard for diabetes, which can accurately reflect blood sugar control in past few months.
By taking a step forward, without the involvement of any bulky or specialized instruments, Abnova has established the portable HbA1c test for the convenience of people. Self-testing for diabetes at home is made possible. Once confirmed as being at high risk for diabetes, individuals can consult with doctors for further follow-up. This kit can also reduce medical cost in countries lack of medical resources. Abnova’s Personal A1c Diabetes Rapid Test has completed Clinical Trial both in Taiwan and China, and has been submitted for marketing permission.
Abnova has also developed an exclusive isolation system for circulating tumor cells and circulating fetal cells. Since the Chinese government has made substantial de-regulations on non-invasive prenatal screening (NIPS) and expanded the two-child policy, China has become one of the largest potential NIPS market. Through the support of Dongguan Biotech and the formation of alliances, Abnova will establish a third-party testing Laboratory and provide NIPS service in China. Starting from the headquarters in Dongguan Songshan Lake (China), Abnova will soon take on an important role in the Chinese market.
*SASAC: State-owned Assets Supervision and Administration Commission of the State Council.
----------------------------------------------------------------------------------------------------------------------------------------------------------------
About Abnova
Abnova has established a comprehensive portfolio of fully integrated solutions and services to address the needs of the clinical research and in vitro diagnostic industry. Abnova’s ISO13485 and GMP certified facility provide its customers and ISO15189 medical service laboratory partner access to monoclonal antibody, ELISA kit, FISH probe, and circulating cell isolation and retrieval system.. (
www.abnova.com)
